Drugs / GZR102
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06974487 | May → Sep 2025 overdue | type 2 diabetes mellitus | Gan & Lee Pharmaceuticals. | Not yet recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07055386 | Aug 2025 → Jun 2026 overdue | type 2 diabetes mellitus | Gan & Lee Pharmaceuticals. | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-06-10 | Gan and Lee Pharmaceuticals, USA | Results Gan & Lee Showcases Multiple Innovative Research Achievements at the American Diabetes Association’s 86th Scientific Sessions ganlee.com ↗
Meanwhile, the GZR102 injection demonstrated promising glucose-lowering and weight-loss potential in diabetic animal models. |
| 2025-04-22 | Gan and Lee Pharmaceuticals, USA | Regulatory Gan & Lee Pharmaceuticals Announces IND Clearance by NMPA for Class 1 New Drug Weekly Fixed Ratio Combination GZR102 ganlee.com ↗ |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-06-10 | Gan and Lee Pharmaceuticals, USA | Gan & Lee Showcases Multiple Innovative Research Achievements at the American Diabetes Association’s 86th Scientific Sessions ganlee.com ↗ |
| 2025-08-08 | Gan and Lee Pharmaceuticals, USA | Gan & Lee Pharmaceuticals Announced First Participant Dosed in Phase 2 Clinical Study of GZR102 Injection, a Once-weekly Fixed-Ratio Combination of Basal Insulin and GLP-1 RA ganlee.com ↗ |
| 2025-05-16 | Gan and Lee Pharmaceuticals, USA | Gan & Lee Pharmaceuticals Announced First Participant Dosed in Phase 1 Clinical Study of GZR102 Injection, a Once-weekly Fixed-Ratio Combination of Basal Insulin and GLP-1 RA ganlee.com ↗ |
| 2025-04-22 | Gan and Lee Pharmaceuticals, USA | Gan & Lee Pharmaceuticals Announces IND Clearance by NMPA for Class 1 New Drug Weekly Fixed Ratio Combination GZR102 ganlee.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GZR102 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07055386 ↗ |
| Route | Subcutaneous | “Administered SC” NCT07055386 ↗ |